×
BioAffinity Technologies EBITDA 2022-2025 | BIAF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
BioAffinity Technologies ebitda from 2022 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
BioAffinity Technologies EBITDA 2022-2025 | BIAF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
BioAffinity Technologies ebitda from 2022 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$225.3B
Amgen (AMGN)
$164.8B
Gilead Sciences (GILD)
$144.5B
Vertex Pharmaceuticals (VRTX)
$120.6B
Bristol Myers Squibb (BMY)
$98.6B
CSL (CSLLY)
$85.4B
GSK (GSK)
$77.7B
Regeneron Pharmaceuticals (REGN)
$60.8B
Alnylam Pharmaceuticals (ALNY)
$42.9B
Argenex SE (ARGX)
$36.2B
BioNTech SE (BNTX)
$27.7B
Royalty Pharma (RPRX)
$20.6B
Insmed (INSM)
$19.7B
Biogen (BIIB)
$19.3B
Illumina (ILMN)
$17.3B
Genmab (GMAB)
$15B
Genmab (GNMSF)
$15B
Incyte (INCY)
$13.6B
Moderna (MRNA)
$13.2B
Exelixis (EXEL)
$12.4B
QIAGEN (QGEN)
$11.5B
BioMarin Pharmaceutical (BMRN)
$11.3B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.2B
Bio-Techne Corp (TECH)
$9.2B
Exact Sciences (EXAS)
$9.1B
Verona Pharma American Depositary Share (VRNA)
$9B
Blueprint Medicines (BPMC)
$8.3B
Legend Biotech (LEGN)
$8B
Roivant Sciences (ROIV)
$7.9B